Información del artículo
Resumen
A pesar de la mejora en el conocimiento de la fisiopatología de la infección grave, de las técnicas diagnósticas, del tratamiento antibiótico, de los cuidados perioperatorios y de la técnica quirúrgica, todavía un porcentaje relevante de pacientes afectados de infección intrabdominal (IAB) desarrolla estadios avanzados de infección y precisa el ingreso en las unidades de cuidados intensivos.
El éxito del tratamiento de la IAB es multifactorial y es necesario saber que la mejor pauta antibiótica puede fracasar si el control del foco de la infección es deficiente o difícil de conseguir. El presente capítulo discute la adecuación del tratamiento antibiótico empírico y los principales patógenos que se han asociado con el fracaso terapéutico. Además, se analizan las situaciones y pacientes de riesgo en los que es precisa una cobertura antibiótica más amplia. El uso excesivo de antibióticos en espectro, cantidad y duración, sin tener en cuenta estos preceptos, puede conducirnos a un modelo de atención poco sostenible en un entorno amenazado por la escasez en la investigación y desarrollo de nuevas moléculas necesarias para atender la aparición de patógenos resistentes a los antibióticos actuales.
Palabras clave:
Infección intraabdominal
Factores de riesgo de fracaso terapéutico
Adecuación del tratamiento antibiótico
Abstract
Despite improvements in our knowledge of the physiopathology of severe infection, diagnostic methods, antibiotic therapy, postoperative care and surgical techniques, a substantial number of patients with intraabdominal infection (IAI) will develop advanced stages of septic insult requiring admission to the intensive care unit.
The success of treatment of IAI is multifactorial and the best antibiotic protocol may be insufficient unless adequate control of the focus of infection has been achieved. The present article discusses the appropriacy of empirical antibiotic therapy and the main pathogens associated with treatment failure. We also analyze the patients at risk of infection with microorganisms requiring broad-spectrum antimicrobial coverage. However, excessive antibiotic treatment, in terms of either spectrum or duration, could jeopardize future patients in an environment already threatened by the scarcity of research and development into new molecules required for the emergence of pathogens resistant to current antibiotics.
Keywords:
Intrabdominal infection
Risk factors of antibiotic treatment failure
Appropriateness of empirical antibiotic therapy
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Barie, L. Hydo, S. Eachempati.
Longitudinal Outcomes of Intra-abdominal Infection Complicated by Critical Illness.
Surg Infect, 5 (2004), pp. 365-373
[2.]
H. Boucher, G. Talbot, J. Bradley, J. Edwards, D. Gilbert, L. Rice, et al.
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America.
Clin Infect Dis, 48 (2009), pp. 1-12
[3.]
K. Kanetake, M. Hayashi, A. Hino, N. Futamura, Y. Mori, H. Takagi, et al.
Primary peritonitis associated with streptococcal toxic shock-like syndrome: Report of a Case.
Surg Today, 34 (2004), pp. 1053-1056
[4.]
D. Mosdell, D. Morris, A. Voltura, D. Pitcher, M. Twiest, R. Milne, et al.
Antibiotic treatment for surgical peritonitis.
Ann Surg, 214 (1991), pp. 543-549
[5.]
J. Tellado, S. Sen, M. Caloto, R. Kumar, G. Nocea.
Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community acquired intra-abdominal infections in Spain.
Scand J Infect Dis, 39 (2007), pp. 947-955
[6.]
A. Sitges-Serra, J. Sancho-Isenser, E. Membrilla, M. Girvent.
Grupo de estudio PEPES (Patógenos emergentes en peritonitis). Estudio de adecuación de la antibioticoterapia empírica en el tratamiento de la infeción intraabdominal complicada.
XXVII Congreso Nacional de Cirugía,
[7.]
P. Montravers, R. Gauzit, C. Muller, J. Marmuse, A. Fichelle, J. Desmonts.
Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy.
Clin Infect Dis, 23 (1996), pp. 486-494
[8.]
A. Roehrborn, L. Thomas, O. Potreck, C. Ebener, C. Ohmann, P. Goretzki, et al.
The microbiology of postoperative peritonitis.
Clin Infec Dis, 33 (2001), pp. 1513-1519
[9.]
J. Chow, V. Satishchandran, T. Snyder, C. Harvey, I. Friedland, M. Dinubile.
In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART).
Surg Infect, 6 (2006), pp. 439-447
[10.]
D. Paterson, F. Rossi, F. Baquero, P. Hsuech, G. Woods, V. Satishchandran, et al.
In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).
J Antimicrob Chemother, 55 (2005), pp. 965-973
[11.]
F. Rossi, F. Baquero, P. Hsuech, D. Paterson, G. Bochicchio, T. Snyder, et al.
In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
J Antimicrob Chemother, 58 (2006), pp. 205-210
[12.]
P. Montravers, A. Lepape, L. Dubreuil, R. Gauzit, Y. Pean, D. Benchimol, et al.
Clinical and microbiolocal profiles and community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study.
J Antimicrob Chemother, 63 (2009), pp. 785-794
[13.]
Members of the American College of Chest Pysicians, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
[14.]
M. Rangel-Fausto, D. Pittet, M. Costigan, T. Hwang, C. Davis, R. Wenzel.
The natural history of SIRS.
JAMA, 273 (1995), pp. 117-123
[15.]
X. Guirao, G. Franch, J. Navinés, M. Casal, M. Juvany, J. Montero, et al.
Monitorización de la proteína C-reactiva en el diagnóstico precoz de las complicaciones mayores en la cirugía colorrectal electiva.
XXVII Congreso Nacional de Cirugía,
[16.]
E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, et al.
Early goaldirected therapy Iin the treatment of severe sepsis and septic shock.
N Engl J Med, 345 (2001), pp. 1368-1377
[17.]
M. Mikkelsen, A. Miltiades, D. Gaieski, M. Goyal, B. Fuchs, C. Shah, et al.
Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock.
Crit Care Med, 37 (2009), pp. 1670-1777
[18.]
H. Nguyen, E. Rivers, G. Moan, E. Abraham, S. Trzeciak, D. Huang, et al.
Review of the literature and emergency department management guidelines.
Ann Emerg Med, 48 (2006), pp. 28-54
[19.]
N. Christou, P. Barie, P. Dellinger, P. Waymack, H. Stone.
Surgical infection society intra-abdominal infection study. Prospective evaluation of management techniques and outcome.
Archives of Surgery, 128 (1993), pp. 193-199
[20.]
H. Wacha, T. Hau, R. Dittmer, C. Ohmann, the Peritonitis Study Group.
Risk factors associated with intraabdominal infections: a prospective multicenter study.
Lagenbeck's Arch Surg, 384 (1999), pp. 24-32
[21.]
K. Bosscha, K. Reijnders, P. Hulstaert, A. Algra, C. Van der Werken.
Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis.
British Journal of Surgery, 84 (1997), pp. 1532-1534
[22.]
F. Álvarez-Lerma.
Modification of empiric antibiotic treatment in patients with penumonia acquired in the intensive care unit. ICY-Acquired Pneumonia Study Group.
Intensive Care Med, 22 (1996), pp. 387-394
[23.]
M. Kollef, G. Sherman, S. Ward, V. Fraser.
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically Ill patients.
Chest, 115 (1999), pp. 462-474
[24.]
C. Luna, A. Famiglietti, R. Absi, A. Videla, F. Nogueira, A. Fuenzalida, et al.
Community-acquired pneumonia.
Chest, 118 (2000), pp. 1344-1354
[25.]
E. Ibrahim, G. Sherman, S. Ward, V. Frase, M. Kollef.
The influence of inadequate antimicrobial treatment of bloodstream infections on patients outcomes in the ICU setting.
Chest, 118 (2000), pp. 146
[26.]
K. Krobot, D. Yin, Q. Zhang, S. Sen, A. Altendorf-Hofmann, J. Scheele, et al.
Effect of inappropiate initial empiric antibiotic therapy on outcome of patients with community-acquiered intrabdominal infections requiring surgery.
Eur J Clin Microbiol Infec Dis, 23 (2004), pp. 682-687
[27.]
M. Baré, X. Castells, A. García, M. Riu, M. Comas, M. Gil-Egea.
Importance of apropiateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections.
Int J Technol Assess Health Care, 22 (2006), pp. 242-248
[28.]
D. Battelmen, M. Callahan, H. Thaler.
Rapid antibiotic delivery and appropiate antibiotic selection reduce lenght of hospital stay of patients with community-acquired pneumonia.
Arch Intern Med, 162 (2002), pp. 682-688
[29.]
M. Sturkenboom, W. Goettsch, G. Picelli, B. Veld, D. Yin, R. De Jong, et al.
Inappropiate initial treatment of secondary intra-abdomial infections leads to increased risk of clinical failure and costs.
Br J Clin Pharmacol, 60 (2005), pp. 438-443
[30.]
H. Dupont, C. Carbon, J. Carlet, Severe Generalized Perintonits Study Group T.
Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalizaed peritonitis: a multicenter randomized controlled trial.
Antimicrob Agents Chemother, 44 (2000), pp. 2028-2033
[31.]
A. Mansour, W. Watson, V. Shayani, J. Pickelman.
Abdominal operation in patients with cirrhosis: still a major surgical challenge.
Surgery, 122 (1997), pp. 730-735
[32.]
M. Falagas, L. Barefoot, J. Griffith, R. Ruthzar, D. Snydman.
Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections.
Eur J Clin Microbiol Infec Dis, 15 (1996), pp. 913-921
[33.]
J. Tellado, A. Sitges-Serra, F. Barcenilla, M. Palomar, R. Serrano, J. Barberán, et al.
Pautas de tratamiento antibiótico empírico de las infecciones intraabdominales.
Rev Esp Quimioterap, 18 (2005), pp. 2
[34.]
A. Sitges-Serra, M. López, M. Girvent, S. Almirall, J. Sancho.
Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis.
Br J Surg, 89 (2002), pp. 361-367
[35.]
M. Gobernado.
Infecciones por bacterias productoras de β-lactamasas.
Infecciones quirúrgicas, pp. 483-486
[36.]
F. Baquero, P. Hsuech, D. Paterson, F. Rossi, G. Biochicchio, G. Gallagher, et al.
In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART).
Surg Infect (Larchmt), 10 (2009), pp. 99-104
[37.]
T. Coque, F. Baquero, R. Cantón.
Increasing prevalence of ESBL-producing enterobacteriacea in Europe.
Eurosurveillance, 13 (2008), pp. 1-11
[38.]
F. Baquero, E. Cercenado, R. Cisterna, M. De la Rosa, J. García-Rodríguez, M. Gobernado, et al.
Patrones de sensiblidad a antimicrobianos e Enterobacterias causantes de infecciones intrabdominales en España: resultados del estudio SMART 2003.
Rev Esp Quimioterap, 19 (2006), pp. 51-59
[39.]
J. Rodríguez-Baño, D.L. Paterson.
A change in the epidemiology of infections due to extended-spectrum ??-lactamase-producing organisms.
Clin Infect Dis, 42 (2006), pp. 935-937
[40.]
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, et al.
Prevalence and spread of extended-spectrum b-lactamase-producing Enterobacteriaceae in Europe.
Clin Microbiol Infect, 14 (2008), pp. 144-153
[41.]
J. Rodríguez-Baño, M. Navarro.
Impacto de las BLEE en los tratamientos empíricos y las políticas antibióticas.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 54-59
[42.]
S. Bratu, D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, et al.
Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.
Arch Intern Med, 165 (2005), pp. 1430-1435
[43.]
D. Gülmez, N. Woodford, M. Pelepou, S. Musthaq, G. Metan, Y. Yakupogullari, et al.
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.
Int J Antimicrob Agents, 31 (2008), pp. 523-526
[44.]
I. Skippen, M. Shemko, J. Turton, M. Kaufmann, C. Palmer, N. Shetty.
Epidemiology of infections caused by extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case control study from a tertiary hospital in London.
J Hosp Infect, 64 (2006), pp. 115-123
[45.]
J. Martínez, J. Aguilar, M. Almela, F. Marco, A. Soriano, F. López, et al.
Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase- producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
J Antimicrob Chemother, 58 (2006), pp. 1082-1085
[46.]
M. Tumbarello, T. Spanu, M. Sanguinetti, R. Citton, E. Montuori, F. Leone, et al.
Bloodstream infections caused by extended-spectrum-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.
Antimicrob Agents Chemother, 50 (2006), pp. 498-504
[47.]
R. Ben-Ami, J. Schwaber, S. Navon-Venezia, D. Schwartz, I. Chmelnitsky, A. Leavitt, et al.
Influx of extended-spectrum β-lactamase-producing enterobacteriaceae into the hospital.
Clin Infect Dis, 42 (2006), pp. 925-934
[48.]
R. Colodner, W. Rock, B. Chazan, N. Keller, N. Guy, W. Sakran, et al.
Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.
Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 163-167
[49.]
C. Peña, C. Gudiol, F. Tubau, M. Saball, M. Pujol, M. Domínguez, et al.
Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients.
Clin Microbiol Infect, 12 (2006), pp. 279-284
[50.]
B. Swenson, R. Metzger, T. Hedrick, S. McElearney, H. Evans, R. Smith, et al.
Choosing antibiotics for intra-abdominal infections: what do we mean by “high risk”?.
Surg Infect (Larchmt), 10 (2009), pp. 29-39
[51.]
M. DiNubile, I. Friendland, C. Chan, M. Motyl, H. Giezel, M. Shivaprakash, et al.
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.
Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 443-449
[52.]
A. Harris, J. McGregor, J. Johnson, S. Strauss, A. Moore, H. Standiford, et al.
Risk factors for colonization with extended-spectrum β-lactamase– producing bacteria and intensive care unit admission.
Emerg Infect Dis, 13 (2007), pp. 1144-1149
[53.]
C. Kang, S. Kim, W. Park, K. Lee, H. Kim, E. Kim, et al.
Boodstream infections caused by antibiotic-resistans gram-negative bacilli: risk factors and impact of inappropiate initial antimicrobial therapy on outcome.
Antimicrob Agents Chemother, 49 (2005), pp. 760-766
[54.]
D. Raymond, S. Pelletier, T. Crabtree, H. Evans, T. Pruett, R. Sawyer.
Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients.
Crit Care Med, 31 (2003), pp. 1035-1041
[55.]
D. Genné, A. Menetrey, P. Indino, C. Sénéchaud, H.H. Siegriest.
Treatment of secondary peritonitis: is a less expensive broad-spectrum antibiotic as effective as a carbapenem?.
Dig Surg, 20 (2003), pp. 415-420
[56.]
A. Sotto, J. Lefrant, P. Fabbro-Peray, L. Muller, J. Tafuri, F. Navarro, et al.
Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis.
J Antimicrob Chemother, 50 (2002), pp. 569-576
[57.]
J. Bradley, J. Garau, K. Roston, J. Qujinn.
Carbapenems in clinical practice: a guide to the use in serious infection.
Int J Antimicrob Agents, 11 (1999), pp. 93
[58.]
S. Kusachi, Y. Sumiyama, Y. Arima, Y. Yoshida, H. Tanaka, Y. Nakamura, et al.
Isolated bacteria and drug susceptibility associated with the course of surgical site infections.
J Infect Chemother, 13 (2007), pp. 166
[59.]
T. Babinchak, E. Ellis-Grose, N. Dartois, G. Rose, E. Loh, Tigecycline 301 and 306 Study G.
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Clin Infect Dis, 41 (2005), pp. S354-S366
[60.]
H. Dupont.
The empiric treatment of nosocomial intra-abdominal infections.
Int J Infec Dis, 11 (2007), pp. S1-6
[61.]
R. Burnett, D. Haverstock, E. Dellinger, H. Reinhart, J. Bohnen, O. Rotstein, et al.
Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.
Surgery, 118 (1995), pp. 716-723
[62.]
A. Onderdonk, J. Barlett, T. Louie, N. Sullivan-Seigler, S. Gorbach.
Microbial synergy in experimental intra-abdomninal abscess.
Infec Immun, 13 (1976), pp. 22-26
[63.]
R. Moellering.
Enterococcus species, Streptococcus bovis, and Leuconostoc species.
Mandel, Douglas, and Bennett, pp. 2411-2421
[64.]
R. Dahms, E. Johnson, C. Statz, J. Lee, D. Dunn, G. Beilman.
Third-generation cephalosporins and vancomycin as risk factors for postorpeative vancomycin-resistant enterococcus infection.
Arch Surg, 133 (1998), pp. 1343-1346
[65.]
A. Röhrborn, H. Wacha, U. Schöffel, A. Billing, P. Aeberhard, B. Beghard, et al.
Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial.
Surg Infect, 1 (2000), pp. 95-107
[66.]
J. Solomkin, A. Yellin, O. Rostein, N. Christou, E. Dellinger, J. Tellado, et al.
Ertapenem versus piperacillin-tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comprative phase III trial.
Ann Surg, 237 (2003), pp. 235-245
[67.]
S. Borbone, C. Cascone, M. Santagati, M. Mezzatesta, M. Stefani.
Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Int J Antimicrob Agents, 28 (2006), pp. 396-401
[68.]
N. Namias, J. Solomkin, E. Jensen, J. Tomassini, M. Abramson.
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra- abdominal infections in hospitalized adults.
Surg Infect, 8 (2007), pp. 15-28
[69.]
P. Barie, S. Vogel, E. Dellinger, O. Rostein, J. Solomkin, J. Yang, et al.
A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.
Arch Surg, 132 (1997), pp. 1294-1302
[70.]
K. Itani, S. Wilson, S. Award, E. Jensen, T. Finn, M. Abramson.
Ertapenem versus cefotetan prophylaxis in elective colorectal surgery.
N Engl J Med, 355 (2006), pp. 2640-2651
[71.]
B. Mirelis Otero, G. Prats Pastor.
Conceptos de microbiología aplicada.
Infecciones Quirúrgicas, pp. 27-46
[72.]
H. Boucher, C. Wennersten, G. Eliopoulos.
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Antimicrob Agents Chemother, 44 (2000), pp. 2225-2229
[73.]
C. Betriu, I. Rodríguez-Avial, B. Ali-Sánchez, M. Gómez, J. Álvarez, J. Picazo, et al.
In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.
Antimicrob Agents Chemother, 46 (2002), pp. 892-895
[74.]
D. Dean, K. Buechard.
Fungal Infections in Surgical Patients.
Am J Surg, 171 (1996), pp. 374-382
[75.]
J. Nolla-Salas, A. Sitges-Serra, C. León-Gil, J. Martínez-Gonzalez, M. León-Regidor, P. Ibáñez-Lucia, et al.
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy.
Intensive Care Med, 23 (1997), pp. 23-30
[76.]
P. Sandven, K. Giercksky, the NORGAS Group, and the Norweigian Yeast Study Group.
Yeast colonization in surgical patients with intra-abdominal perforations.
Eur J Clin Microbiol Infect Dis, 20 (2001), pp. 475-481
[77.]
C. León, S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, F. Álvarez-Lerma, et al.
A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization*.
Crit Care Med, 34 (2006), pp. 730-737
[78.]
J. Vincent, E. Anaissie, H. Bruining, W. Demajo, M. El-Ebiary, J. Haber, et al.
Epidemiology, diagnosis and treatment od systemic Candida infection in surgical patients under intensive care.
Intensive Care Med, 24 (1998), pp. 206-216
[79.]
C. Weiss III., C. Statz, R. Dahms, M. Remucal, D.G.B.J. Dunn.
Six years of surgical wound infection surveillance at a tertiary care center: review of the microbiologic and epidemiological aspects of 20,007 wounds.
Arch Surg, 134 (1999), pp. 1041-1048
[80.]
M. Levison, D. Zeigler.
Correlation of APACHE II score, drainage technique and outcome in postoperative intra-abdominal abscess.
Surg Gynecol Obstet, 172 (1991), pp. 89-94
[81.]
R. Brolin, L. Flancbaum, F. Ercoli, L. Milgrim, J. Bocage, A. Blum, et al.
Limitations of percutaneous catheter drainage of abdominal abscesses.
Surg Gynecol Obstet, 173 (1991), pp. 203-210
[82.]
P. Montravers, H. Dupont, R. Gauzit, B. Veber, C. Auboyer, P. Blin, et al.
Candida as a risk factor for mortality in peritonitis.
Crit Care Med, 34 (2006), pp. 646-652
[83.]
N. Pultz, U. Stiefel, M. Ghannoum, M. Helfand, C. Dosnkey.
Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice.
Antimicrob Agents Chemother, 49 (2005), pp. 438-440
[84.]
British Society for Antimicrobial Chemotherapy.
Management of deep Candida infection in surgical and intensive care unit patients.
Intensive Care Med, 20 (1994), pp. 522-528
[85.]
S. Blot, K. Vandewoude, J. Waele.
Candida peritonitis.
Curr Opin Crit Care, 13 (2007), pp. 195-199
[86.]
J. Nolla-Salas, J. Torres-Rodríguez, S. Grau, F. Isbert, T. Torrella, M. Riveiro, et al.
Succesful treatment with liposomal amphoitercin B of an intraabdominal abscess due to Candida norvegensis associates with a gore-tex-mesh infection.
Scand J Infect Dis, 32 (2000), pp. 560-562
[87.]
G. Pier, R. Ramphal.
Pseudomonas aeruginosa.
Mandell, Douglas and Bennett's. Principles and practice of infectious diseases, pp. 2587-2615
[88.]
C. Kang, S. Kim, H. Kim, S. Park, Y. Choe, M. Oh, et al.
Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
Clin Infect Dis, 37 (2003), pp. 745-751
[89.]
P. Berthelot, F. Grattard, P. Mahul, R. Jospé, C. Venet, A. Carricajo, et al.
Prospective study of nosocomial colonization and infection due to Pseudomonas aeruginosa in mechanically ventilated patients.
Intensive Care Med, 27 (2001), pp. 503-512
[90.]
A. Kumar, D. Roberts, K. Wood, B. Light, J. Parrillo, S. Sharma, et al.
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.
Crit Care Med, 34 (2006), pp. 1589-1596
Copyright © 2010. Elsevier España S.L.. Todos los derechos reservados
